Abstract
The cornea is physiologically avascular. Following a corneal injury, wound healing often proceeds without neovascularization (NV); however, corneal NV may be induced during wound healing in certain inflammatory, infectious, degenerative, and traumatic states. Such states disrupt the physiologic balance between pro-angiogenic and antiangiogenic mediators, favoring angiogenesis. Contributors to such states are matrix metalloproteinases (MMPs), which are key factors in both extracellular matrix remodeling and angiogenesis. Similarly, vascular endothelial growth factor A (VEGF-A) and basic fibroblast growth factor (bFGF) exert pro-angiogenic effects. Here, we elaborate on the facilitative role of MMPs—specifically Membrane Type 1 MMP (MT1-MMP, MMP14)—in corneal NV. Additionally, we provide new insight into the signaling relating to MT1-MMP, Ras, and ERK in the bFGF-induced VEGF-A expression pathways within the corneal fibroblasts.
Keywords: Basic FGF, corneal angiogenesis, ERK, MT1-MMP, Ras, VEGF-A, homeostasis, pro-angiogenic effect, Basic fibroblast growth factor (bFGF), vascular endothelial growth factor.
Protein & Peptide Letters
Title:MT1-MMP Modulates bFGF-Induced VEGF-A Expression in Corneal Fibroblasts
Volume: 19 Issue: 12
Author(s): Kyu-Yeon Han, Daoud C. Fahd, Makambo Tshionyi, Norma Allemann, Sandeep Jain, Jin-Hong Chang and Dimitri T. Azar
Affiliation:
Keywords: Basic FGF, corneal angiogenesis, ERK, MT1-MMP, Ras, VEGF-A, homeostasis, pro-angiogenic effect, Basic fibroblast growth factor (bFGF), vascular endothelial growth factor.
Abstract: The cornea is physiologically avascular. Following a corneal injury, wound healing often proceeds without neovascularization (NV); however, corneal NV may be induced during wound healing in certain inflammatory, infectious, degenerative, and traumatic states. Such states disrupt the physiologic balance between pro-angiogenic and antiangiogenic mediators, favoring angiogenesis. Contributors to such states are matrix metalloproteinases (MMPs), which are key factors in both extracellular matrix remodeling and angiogenesis. Similarly, vascular endothelial growth factor A (VEGF-A) and basic fibroblast growth factor (bFGF) exert pro-angiogenic effects. Here, we elaborate on the facilitative role of MMPs—specifically Membrane Type 1 MMP (MT1-MMP, MMP14)—in corneal NV. Additionally, we provide new insight into the signaling relating to MT1-MMP, Ras, and ERK in the bFGF-induced VEGF-A expression pathways within the corneal fibroblasts.
Export Options
About this article
Cite this article as:
Han Kyu-Yeon, C. Fahd Daoud, Tshionyi Makambo, Allemann Norma, Jain Sandeep, Chang Jin-Hong and T. Azar Dimitri, MT1-MMP Modulates bFGF-Induced VEGF-A Expression in Corneal Fibroblasts, Protein & Peptide Letters 2012; 19 (12) . https://dx.doi.org/10.2174/092986612803521639
DOI https://dx.doi.org/10.2174/092986612803521639 |
Print ISSN 0929-8665 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5305 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Immunotherapy for Prostate Cancer
Current Pharmaceutical Design A Prooxidant Mechanism for the Anticancer and Chemopreventive Properties of Plant Polyphenols
Current Drug Targets PPARγ Agonists in Combination Cancer Therapies
Current Cancer Drug Targets Targeting Kinase Interaction Networks: A New Paradigm in PPI Based Design of Kinase Inhibitors
Current Topics in Medicinal Chemistry Chemical Synthesis, Characterisation and Biological Evaluation of Furanic- Estradiol Derivatives as Inhibitors of 17β-Hydroxysteroid Dehydrogenase Type 1
Medicinal Chemistry Is Fibroblast Growth Factor Receptor 4 a Suitable Target of Cancer Therapy?
Current Pharmaceutical Design Pharmacological Profile and Pharmacogenomics of Anti-Cancer Drugs Used for Targeted Therapy
Current Cancer Drug Targets Novel HSP90 Inhibitor NVP-AUY922 Enhances the Anti-tumor Effect of Temsirolimus Against Oral Squamous Cell Carcinoma
Current Cancer Drug Targets Caveolae and Caveolin-1: Novel Potential Targets for the Treatment of Cardiovascular Disease
Current Pharmaceutical Design Intracellular Proton Pumps as Targets in Chemotherapy: V-ATPases and Cancer
Current Pharmaceutical Design The Anti-Proliferative Effect of a Newly-Produced Anti-PSCA-Peptide Antibody by Multiple Bioinformatics Tools, on Prostate Cancer Cells
Recent Patents on Anti-Cancer Drug Discovery Recent Patents on Carotenoid Production in Microbes
Recent Patents on Biotechnology Molecular Imaging with Nucleic Acid Aptamers
Current Medicinal Chemistry Targeted Therapies in Gynecologic Cancers
Current Cancer Drug Targets Autophagy as a Molecular Target of Flavonoids Underlying their Protective Effects in Human Disease
Current Medicinal Chemistry Targeting RSK: An Overview of Small Molecule Inhibitors
Anti-Cancer Agents in Medicinal Chemistry A Comparison of Physicochemical Property Profiles of Marketed Oral Drugs and Orally Bioavailable Anti-Cancer Protein Kinase Inhibitors in Clinical Development
Current Topics in Medicinal Chemistry Redox-inactive Analogue of Tocotrienol as a Potential Anti-cancer Agent
Anti-Cancer Agents in Medicinal Chemistry Therapeutic Cancer Vaccines: At Midway Between Immunology and Pharmacology
Current Cancer Drug Targets The Roles of Vitamin D and Its Analogs in Inflammatory Diseases
Current Topics in Medicinal Chemistry